The Independent on MSN4mon
Donanemab patient: ‘The drug kept me feeling normal, but i’m scared about what happens next’
Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new ...
MedPage Today24d
Alzheimer's Patients May Gain Months of Independent Living With Treatment
Treatment with donanemab (Kisunla) in patients with a baseline CDR-SB score of 2 who had low to medium tau would extend independence in IADLs by 13 months (95% CI 6-24 months). Alzheimer's ...
News Medical26d
Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost?
New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly ...